Patient information
| . | Acalabrutinib 100 mg BD (n = 8) . | Ibrutinib 480 mg OD (n = 6) . | Btk inhibitor naïve (n = 5) . |
|---|---|---|---|
| Age, median (range), y | 68 (53-80) | 68 (60-77) | 78 (60-80) |
| Sex, n (%) | |||
| Female | 2 (25) | 3 (50) | 3 (60) |
| Male | 6 (75) | 3 (50) | 2 (40) |
| Diagnosis, n (%) | |||
| CLL | 7 (87.5) | 6 (100) | 5 (100) |
| Mantle cell lymphoma | 1 (12.5) | — | — |
| Laboratory parameters | |||
| Hemoglobin, median (range), g/L | 139 (113-155) | 131 (109-147) | 140 (117-148) |
| Platelet count, median (range), ×109/L | 148.5 (35-228) | 114 (58-197) | 118 (109-274) |
| Clinical details, n (%) | |||
| Concurrent antiplatelet drugs | — | — | — |
| Concurrent anticoagulants | 1 (13)* | — | — |
| Inherited bleeding disorders | — | — | — |
| Duration of Btk inhibitor, median (range), mo | 21.5 (19-32) | 19 (2-39) | — |
| Active bleeding at time of recruitment | — | — | — |
| Bleeding on Btk inhibitor, n (%)† | |||
| None | 3 (38) | 5 (83) | — |
| Grade 1 | 2 (25) | 1 (17) | — |
| Grade 2 | 3 (38) | — | — |
| Response to Btk inhibitor, n (%)‡ | |||
| Complete remission | 5 (63) | 3 (50) | — |
| Partial remission | 3 (38) | 3 (50) | — |
| Stable or progressive disease | — | — | — |
| . | Acalabrutinib 100 mg BD (n = 8) . | Ibrutinib 480 mg OD (n = 6) . | Btk inhibitor naïve (n = 5) . |
|---|---|---|---|
| Age, median (range), y | 68 (53-80) | 68 (60-77) | 78 (60-80) |
| Sex, n (%) | |||
| Female | 2 (25) | 3 (50) | 3 (60) |
| Male | 6 (75) | 3 (50) | 2 (40) |
| Diagnosis, n (%) | |||
| CLL | 7 (87.5) | 6 (100) | 5 (100) |
| Mantle cell lymphoma | 1 (12.5) | — | — |
| Laboratory parameters | |||
| Hemoglobin, median (range), g/L | 139 (113-155) | 131 (109-147) | 140 (117-148) |
| Platelet count, median (range), ×109/L | 148.5 (35-228) | 114 (58-197) | 118 (109-274) |
| Clinical details, n (%) | |||
| Concurrent antiplatelet drugs | — | — | — |
| Concurrent anticoagulants | 1 (13)* | — | — |
| Inherited bleeding disorders | — | — | — |
| Duration of Btk inhibitor, median (range), mo | 21.5 (19-32) | 19 (2-39) | — |
| Active bleeding at time of recruitment | — | — | — |
| Bleeding on Btk inhibitor, n (%)† | |||
| None | 3 (38) | 5 (83) | — |
| Grade 1 | 2 (25) | 1 (17) | — |
| Grade 2 | 3 (38) | — | — |
| Response to Btk inhibitor, n (%)‡ | |||
| Complete remission | 5 (63) | 3 (50) | — |
| Partial remission | 3 (38) | 3 (50) | — |
| Stable or progressive disease | — | — | — |
BD, twice daily; OD, once daily.
Dabigatran 150 mg twice daily.
Common Terminology Criteria for Adverse Events grading scale.
International Workshop on Chronic Lymphocytic Leukemia criteria for chronic lymphocytic leukemia; positron emission tomography computed tomography criteria for mantle cell lymphoma.